Osaic Holdings’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Osaic Holdings’s Portfolio TCRR Stock Details TCRR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,801	Closed	-$2.7K	–	7684
2023 Q1	$2.7K	Buy	1,801 +451	+33%	+$607	﹤0.01%	6592
2022 Q4	$2K	Buy	1,350 +552	+69%	+$744	﹤0.01%	6761
2022 Q3	$1K	Hold	798	–	–	﹤0.01%	7168
2022 Q2	$2K	Hold	798	–	–	﹤0.01%	6982
2022 Q1	$2K	Buy	798 +49	+7%	+$154	﹤0.01%	6948
2021 Q4	$3K	Sell	749 -151	-17%	-$944	﹤0.01%	6951
2021 Q3	$8K	Buy	900 +537	+148%	+$7.59K	﹤0.01%	6355
2021 Q2	$6K	Buy	363 +319	+725%	+$6.44K	﹤0.01%	6326
2021 Q1	$1K	Buy	44 +24	+120%	+$654	﹤0.01%	6732
2020 Q4	$1K	Buy	+20	New	+$506	﹤0.01%	6321

Osaic Holdings's TCRR Position: Q2 2023 in Review

Osaic Holdings sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 1,801 shares — an estimated $2.7K sold.

Osaic Holdings first reported a position in TCRR in Q4 2020 and held it in 10 quarters. The position peaked at $8K in Q3 2021. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.

Osaic Holdings reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Osaic Holdings sold 1,801 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $2.7K.
Osaic Holdings first reported a position in TCR2 Therapeutics Inc. Common Stock in Q4 2020 and held it in 10 quarters.
Osaic Holdings's TCR2 Therapeutics Inc. Common Stock position peaked at $8K in Q3 2021.
0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.

Based on Osaic Holdings's 13F filing for Q2 2023, filed 10 Aug 2023.